Event-Driven Stocks

CHINOOK THERAPEUTICS, INC.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 3 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue$6.1M$51.6M$827,000$3.9M$6.6M$17.2M
Operating income−$185.1M−$99.0M−$56.2M−$20.0M−$101.4M−$106.5M
Net income−$187.9M−$102.9M−$81.6M−$46.5M−$21.5M−$91.9M
Total assets$574.1M$563.8M$429.0M$15.7M$357.5M$445.1M
Total liabilities$132.1M$110.2M$94.4M$37.0M$222.2M$207.7M
Equity$441.9M$453.6M$334.6M−$41.1M−$681,000$237.5M
EPS (diluted)$-2.92$-2.26$-6.20$-0.29$-0.28$-0.32
Shares out.55.0M42.4M80.8M79.7M81.0M68.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
−3020.3%
Net margin
−3065.7%
Return on equity
−42.5%
Return on assets
−32.7%
Return on capital (ROCE)
−35.4%
Liabilities / assets
23.0%
Debt / equity
0.30×
Book value / share
$8.04
Revenue growth (YoY)
−88.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
2.79safe
Accruals / assets
−12.3%clean
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
40
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 3 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.